Role Summary
The Patient Engagement Manager position is a contract part-time opportunity for an individual to impactfully contribute to ensuring that the patient voice is incorporated into Lexeo program development and key initiatives. Areas of focus include Friedreich ataxia cardiomyopathy (FA-CM) and Plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM) programs. We seek candidates with the desire to make a difference for patient communities and to contribute cross-functionally across Lexeo.
As a member of the Medical Affairs team, this key role serves as a liaison among patients, families, advocates, the community, and Lexeo. The Patient Engagement Manager supports Lexeo’s role as a trusted partner to rare disease communities and leader in cutting-edge science by identifying unmet needs in patient communities, developing patient materials and external communications, and by representing Lexeo at patient community events.
This individual will be part of a team shaping the therapeutic area landscape for gene therapy launch readiness and joining Lexeo during an expansion phase and an exciting time, offering an opportunity for professional development and advancement.
Desired Candidate Profile
In addition to the required qualifications listed below for this role, we are seeking a team member who is highly motivated and compassionate with a proactive approach to their work. An individual who thinks outside the box, is solution-driven, open and adaptable to change, and wants to meaningfully contribute to shaping Patient Engagement at Lexeo will thrive in this role!
We are currently seeking part-time support up to 25 hours per week, with the ability to eventually increase to 40 hours per week.
If this sounds like you, we welcome you to apply!
An individual located in the Eastern time zone or willing to work Eastern time zone hours is preferred. Travel will be required to attend congresses and meetings pertinent to the role and to the NYHQ Lexeo office as necessary.
About Lexeo
Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreich’s Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact.
Our work culture is a hybrid model with 2 days/week in the New York City office and 3 days working from home.
Lexeo Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
We may use artificial intelligence (AI) tools to support parts of the hiring process, such as reviewing applications, analyzing resumes, or assessing responses. These tools assist our recruitment team but do not replace human judgment. Final hiring decisions are ultimately made by humans. If you would like more information about how your data is processed, please contact us.